Haoling Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haoling Cheng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Jing‐Jing Zhao
Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province Zhejiang University School of Medicine Hangzhou China
1 shared publication - Lu Yang
Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province Zhejiang University School of Medicine Hangzhou China
1 shared publication - Lulin Zhang
Department of Neurology, The First Affiliated Hospital, Fujian Medical University, 350005 Fuzhou, Fujian, China
1 shared publication - Quan-Fu Li
Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province Zhejiang University School of Medicine Hangzhou China
1 shared publication Wei Chen
Department of Neurology, The First Affiliated Hospital, Fujian Medical University, 350005 Fuzhou, Fujian, China
1 shared publicationWeibin Huang
Department of Neurology, The First Affiliated Hospital, Fujian Medical University, 350005 Fuzhou, Fujian, China
1 shared publication
Latest Publications
- Open Access
- 30 August 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (8) , 42844
Immune Characteristics of eQTL and Gene Risk Model and the Inhibitory Effect of DCTD and RRAS on Ferroptosis in Glioblastoma
Background: Glioblastoma (GBM) is an extremely aggressive brain tumor, marked by restricted therapeutic possibilities and a generally unfavorable prognosis. GBM’s complexity and heterogeneity necessitate comprehensive genetic and immunological profiling to enhance therapeutic strategies. Methods: The study integrated The Cancer Genome Atlas (TCGA) and Integrative Epidemiology Unit Open Genome-Wide Association Studies (IEU OpenGWAS) data to identify genetic factors influencing GBM using expression quantitative trait loci (eQTL) and genome-wide association studies (GWAS). Mendelian randomization (MR) analysis revealed 250 GBM-associated genes. A GBM risk prediction model was built using Least Absolute Shrinkage and Selection Operator (LASSO) and Cox regression. The research examined immune infiltration, drug response, and mutation profiles to characterize GBM molecular features. Functional enrichment and in vitro experiments validated key findings. Results: The analysis uncovered significant genetic associations with GBM, emphasizing key genes such as follistatin-like 1 (FSTL1), FXYD domain-containing ion transport regulator 5 (FXYD5), Ras-related protein (RRAS), and ring finger protein 216 pseudogene 1 (RNF216P1). The risk model effectively categorized patients into low-risk and high-risk groups, showing significantly worse survival outcomes in the high-risk group. Immune profiling revealed differential infiltration of cancer-associated fibroblasts (CAFs), macrophages, and T cells, which correlated with the expression levels of the genes that were identified. Patients at high risk showed increased sensitivity to chemotherapeutic drugs such as dasatinib and lapatinib, while those at low risk were more responsive to elesclomol and lisitinib. Notably, key genes such as DCMP Deaminase (DCTD) and RRAS were found to regulate ferroptosis, underscoring their potential as therapeutic targets for GBM treatment. Conclusion: This study deepens the understanding of GBM by pinpointing critical genetic markers and elucidating their influence on the tumor immune microenvironment (TME) as well as treatment response. The risk model developed in this study holds promise for enhancing prognostic accuracy and facilitating the personalization of GBM therapy.
- 30 August 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (8) , 42844
Open AccessImmune Characteristics of eQTL and Gene Risk Model and the Inhibitory Effect of DCTD and RRAS on Ferroptosis in Glioblastoma
Background: Glioblastoma (GBM) is an extremely aggressive brain tumor, marked by restricted therapeutic possibilities and a generally unfavorable prognosis. GBM’s complexity and heterogeneity necessitate comprehensive genetic and immunological profiling to enhance therapeutic strategies. Methods: The study integrated The Cancer Genome Atlas (TCGA) and Integrative Epidemiology Unit Open Genome-Wide Association Studies (IEU OpenGWAS) data to identify genetic factors influencing GBM using expression quantitative trait loci (eQTL) and genome-wide association studies (GWAS). Mendelian randomization (MR) analysis revealed 250 GBM-associated genes. A GBM risk prediction model was built using Least Absolute Shrinkage and Selection Operator (LASSO) and Cox regression. The research examined immune infiltration, drug response, and mutation profiles to characterize GBM molecular features. Functional enrichment and in vitro experiments validated key findings. Results: The analysis uncovered significant genetic associations with GBM, emphasizing key genes such as follistatin-like 1 (FSTL1), FXYD domain-containing ion transport regulator 5 (FXYD5), Ras-related protein (RRAS), and ring finger protein 216 pseudogene 1 (RNF216P1). The risk model effectively categorized patients into low-risk and high-risk groups, showing significantly worse survival outcomes in the high-risk group. Immune profiling revealed differential infiltration of cancer-associated fibroblasts (CAFs), macrophages, and T cells, which correlated with the expression levels of the genes that were identified. Patients at high risk showed increased sensitivity to chemotherapeutic drugs such as dasatinib and lapatinib, while those at low risk were more responsive to elesclomol and lisitinib. Notably, key genes such as DCMP Deaminase (DCTD) and RRAS were found to regulate ferroptosis, underscoring their potential as therapeutic targets for GBM treatment. Conclusion: This study deepens the understanding of GBM by pinpointing critical genetic markers and elucidating their influence on the tumor immune microenvironment (TME) as well as treatment response. The risk model developed in this study holds promise for enhancing prognostic accuracy and facilitating the personalization of GBM therapy.
- Open Access
- 9 July 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (9) , e1314
Clinical features and genetic characteristics of homozygous spinocerebellar ataxia type 3
Background: Homozygous spinocerebellar ataxia type 3 (SCA3) patients, which have an expanded cytosine‐adenine‐guanine (CAG) repeat mutation in both alleles of ATXN3, are extremely rare. Clinical features and genetic characteristics of them were seldom studied.Methods: We analyzed seven newly homozygous SCA3 patients from five families and 14 homozygotes reported previously. An additional cohort of 30 heterozygous SCA3 patients were analyzed to compare age at onset (AAO).Results: Two out of seven SCA3 homozygotes had the minimum CAG repeats reported so far (55/56 and 56/58). Five patients appeared peripheral neuropathy and two had mild cognitive impairment. The AAO was significantly inversely correlated with both the large and small expanded CAG repeats (r = −.7682, p < .0001). The AAO was significantly earlier in homozygous SCA3 than heterozygous ones (32.81 ± 11.86 versus. 49.90 ± 9.73, p < .0001). In addition, the AAO of our seven homozygotes is elder compared to those reported previously (41.29 years vs. 28.57 years), which may be related to the fewer CAG repeats in our seven patients.Conclusion: Gene dosage effect may play an important role in the AAO and severity of disease, and homozygosity for ATXN3 enhances phenotypic severity. Our findings expand clinical features and genetic characteristics of homozygous SCA3 patients.
- 9 July 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (9) , e1314
Open AccessClinical features and genetic characteristics of homozygous spinocerebellar ataxia type 3
Background: Homozygous spinocerebellar ataxia type 3 (SCA3) patients, which have an expanded cytosine‐adenine‐guanine (CAG) repeat mutation in both alleles of ATXN3, are extremely rare. Clinical features and genetic characteristics of them were seldom studied.Methods: We analyzed seven newly homozygous SCA3 patients from five families and 14 homozygotes reported previously. An additional cohort of 30 heterozygous SCA3 patients were analyzed to compare age at onset (AAO).Results: Two out of seven SCA3 homozygotes had the minimum CAG repeats reported so far (55/56 and 56/58). Five patients appeared peripheral neuropathy and two had mild cognitive impairment. The AAO was significantly inversely correlated with both the large and small expanded CAG repeats (r = −.7682, p < .0001). The AAO was significantly earlier in homozygous SCA3 than heterozygous ones (32.81 ± 11.86 versus. 49.90 ± 9.73, p < .0001). In addition, the AAO of our seven homozygotes is elder compared to those reported previously (41.29 years vs. 28.57 years), which may be related to the fewer CAG repeats in our seven patients.Conclusion: Gene dosage effect may play an important role in the AAO and severity of disease, and homozygosity for ATXN3 enhances phenotypic severity. Our findings expand clinical features and genetic characteristics of homozygous SCA3 patients.